BioMarin Pharmaceutical Inc. BMRN | NASDAQ
Company Overview:
6.3 Year Performance Metrics:
Unlock All Reports & Research Dividend Stocks like a BOSS!
BMRN Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for BMRN
Based on past 6.3-year performance, here are BMRN growth metrics:
Share price CAGR of -6.87%
Dividend CAGR of +0%
Using BMRN CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| BMRN (DRIP) | BMRN - No DRIP | |
|---|---|---|
| Current Price | $62.71 | $62.71 |
| Start Shares | 159.46 | 159.46 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 159.46 | 159.46 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $33.06 | $62.71 |
| Total Dividends | $0 | $0 |
| Final Value | $5,272 | $10,000 |
NOTE: Above numbers are our estimate based on BMRN's Dividend and Price CAGR over past 6.3 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Company Info
BioMarin Pharmaceutical Inc. (BMRN) had its IPO on 1999-07-26, and is trader on NASDAQ stock exchange.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
BMRN website: https://www.biomarin.com
